A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)
A Pilot Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)
Sponsor: Massachusetts General Hospital
Terminated
This was an inpatient study, but PI left inpatient service at MGH
Other terminated trials from Massachusetts General Hospital
Other Depression trials with similar outcome
Listed as NCT01312844, this PHASE2 trial focuses on Depression and remains terminated or withdrawn. Sponsored by Massachusetts General Hospital, it has been updated 8 times since 2010, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated · Phase: NA → PHASE2
-
Jan 2017 — Jun 2017 [monthly]
Unknown Status NA
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .